{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-016929","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.542766+00:00","generated_at":"2026-05-26T04:40:17.989069+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Milestone Pharma provides corporate presentation ahead of March 27 PDUFA for CARDAMYST","bullets":["NDA for CARDAMYST (etripamil) nasal spray remains under FDA review with PDUFA date of March 27, 2025.","Presentation outlines potential commercial launch strategy, but product is not yet approved.","Company actively preparing for launch pending FDA decision.","Presentation used at investor meetings; available on company website."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-016929","json":"https://secwatch.observer/filing/0001104659-25-016929.json","markdown":"https://secwatch.observer/filing/0001104659-25-016929.md","text":"https://secwatch.observer/filing/0001104659-25-016929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/0001104659-25-016929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/tm257508d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:40:17.989069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}